- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about REGN
Recent news which mentions REGN
From Motley Fool
Is Merck Stock a Buy?
November 20, 2021
From Motley Fool
Why Connect Biopharma Stock Is Crashing Today
November 19, 2021
From Motley Fool
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
From Benzinga
From Motley Fool
From Benzinga
5 Stocks To Watch For November 15, 2021
November 15, 2021
From Benzinga
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
November 12, 2021
From Benzinga
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
November 11, 2021
From Benzinga
Better COVID Stock: Merck vs. Pfizer
November 09, 2021
From Motley Fool
From Benzinga
U.S. reopens to vaccinated travelers from 33 countries after 18 months, as global tally of COVID-19 cases tops 250 million
November 08, 2021
Tickers
REGN
Tags
REGN
From MarketWatch
From Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
From Benzinga
From Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
November 05, 2021
Tickers
REGN
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
November 05, 2021
From Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
From Benzinga
3 Reasons Why Investors Should Love Regeneron's Q3 Update
November 05, 2021
Tickers
REGN
From Motley Fool
Regeneron Pharmaceuticals Inc (REGN) Q3 2021 Earnings Call Transcript
November 04, 2021
Tickers
REGN
From Motley Fool
7 European Stocks to Buy to Diversify Your Portfolio
November 04, 2021
From InvestorPlace
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
From Benzinga
Is There Any Hope for Atea Pharmaceuticals Stock?
November 04, 2021
From Motley Fool
Healthcare Stocks Subject to Government Policy
November 02, 2021
From Benzinga
A Pfizer Drug Moves Closer to Approval in Another Important Indication
November 02, 2021
From Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
From Benzinga
Will Regeneron Be Worth More Than Amazon by 2030?
October 28, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.